Search research articles
Contact Us
Filters
Showing results (1-10 of 81) with videos related to
Page
of 9
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 7, 2019
Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment
Scott F Huntington
The Oncologist
|
November 24, 2020
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients
Mengyang Di, Scott F Huntington, Adam J Olszewski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2015
Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission
Scott F Huntington, Jakub Svoboda, Jalpa A Doshi
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 10, 2023
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
Jan Philipp Bewersdorf, Scott F Huntington, Amer M Zeidan
American Journal of Clinical Pathology
|
August 9, 2023
Helicobacter pylori-negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: A clinicopathologic analysis
Sean X Gu, Alexa J Siddon, Scott F Huntington, et al.
JAMA Network Open
|
January 12, 2021
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer
Kishan K Patel, Stacey Stein, Jill Lacy, et al.
Journal of Health Economics and Outcomes Research
|
November 9, 2022
Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis
Scott F Huntington, Sreevalsa Appukkuttan, Wenyi Wang, et al.
Immunotherapy
|
May 27, 2022
Barriers and solutions to improve access for chimeric antigen receptor therapies
Sachin Kamal-Bahl, Justin T Puckett, Indranil Bagchi, et al.
Leukemia & Lymphoma
|
January 29, 2015
Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma
Scott F Huntington, Sunita D Nasta, Stephen J Schuster, et al.
Leukemia & Lymphoma
|
June 21, 2021
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Kishan K Patel, Terri Parker, Mengyang Di, et al.
Page
of 9
Search research articles
Search
Showing results (1-10 of 81) with videos related to
Sort By:
Page
of 9
Hematology. American Society of Hematology. Education Program
|
December 7, 2019
Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment
Scott F Huntington
The Oncologist
|
November 24, 2020
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients
Mengyang Di, Scott F Huntington, Adam J Olszewski
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2015
Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission
Scott F Huntington, Jakub Svoboda, Jalpa A Doshi
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 10, 2023
Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?
Jan Philipp Bewersdorf, Scott F Huntington, Amer M Zeidan
American Journal of Clinical Pathology
|
August 9, 2023
Helicobacter pylori-negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: A clinicopathologic analysis
Sean X Gu, Alexa J Siddon, Scott F Huntington, et al.
JAMA Network Open
|
January 12, 2021
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer
Kishan K Patel, Stacey Stein, Jill Lacy, et al.
Journal of Health Economics and Outcomes Research
|
November 9, 2022
Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis
Scott F Huntington, Sreevalsa Appukkuttan, Wenyi Wang, et al.
Immunotherapy
|
May 27, 2022
Barriers and solutions to improve access for chimeric antigen receptor therapies
Sachin Kamal-Bahl, Justin T Puckett, Indranil Bagchi, et al.
Leukemia & Lymphoma
|
January 29, 2015
Utility of interim and end-of-treatment [(18)F]-fluorodeoxyglucose positron emission tomography-computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma
Scott F Huntington, Sunita D Nasta, Stephen J Schuster, et al.
Leukemia & Lymphoma
|
June 21, 2021
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Kishan K Patel, Terri Parker, Mengyang Di, et al.
Page
of 9